SCHEMBL892158

SCHEMBL892158

CN(C)/C=N/C1=NC2(C(=O)N1C)c1cc(O)ccc1C[C@H]1CCOC[C@@H]12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSD P07339 14/20 0.49
BACE1 P56817 14/20 0.49
OPRM1 P35372 3/20 0.31
GRIN2D O15399 3/20 0.31
GRIN3B O60391 3/20 0.31
GRIN1 Q05586 3/20 0.31
GRIN2A Q12879 3/20 0.31
GRIN2B Q13224 3/20 0.31
GRIN2C Q14957 3/20 0.31
GRIN3A Q8TCU5 3/20 0.31
SLC22A1 O15245 2/20 0.31
SLC6A4 P31645 2/20 0.31
SCN1A P35498 2/20 0.31
MRGPRX2 Q96LB1 2/20 0.31
SCN2A Q99250 2/20 0.31
SCN3A Q9NY46 2/20 0.31
SIGMAR1 Q99720 2/20 0.31
OPRD1 P41143 2/20 0.31
ADRA2A P08913 1/20 0.31
OPRK1 P41145 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL892159 1.00 CTSD (0.49) CTSDBACE1OPRM1GRIN2DGRIN3B
SCHEMBL10209463 0.84 CTSD (0.53) CTSDBACE1OPRM1GRIN2DGRIN3B
SCHEMBL892335 0.83 CTSD (0.46) CTSDBACE1
SCHEMBL10209455 0.82 BACE1 (0.66) CTSDBACE1
SCHEMBL892429 0.82 BACE1 (0.66) CTSDBACE1
SCHEMBL891952 0.69 BACE1 (0.64) CTSDBACE1
SCHEMBL882561 0.69 BACE1 (0.64) CTSDBACE1
SCHEMBL10209459 0.67 BACE1 (0.49) CTSDBACE1
SCHEMBL891687 0.66 OPRK1 (0.37) CTSDBACE1OPRM1OPRD1OPRK1
SCHEMBL891688 0.66 OPRK1 (0.37) CTSDBACE1OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120083501-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083501-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES BACE1, PSEN1, PSEN2 CTSD 224/4885BACE1 1/4885OPRM1 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.